https://independentpeptidenews.com/ Peptide dossiers, each claim linked to a primary document. Volunteer-run. Not medical advice. Dates are the last day we changed each page. en-us Mon, 02 Nov 2026 12:00:00 +0000 https://independentpeptidenews.com/peptides/thymalin/https://independentpeptidenews.com/peptides/thymalin/Mon, 02 Nov 2026 12:00:00 +0000Thymalin dossier: its Russian registration as a thymus extract, published research from a small set of Russian groups, and what FDA does and does not say, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/semax/https://independentpeptidenews.com/peptides/semax/Mon, 02 Nov 2026 12:00:00 +0000Semax dossier: FDA briefing and safety-risk listing, HHS enforcement policy, Russian registration, WADA status, published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/selank/https://independentpeptidenews.com/peptides/selank/Mon, 02 Nov 2026 12:00:00 +0000Selank dossier: FDA safety-risk listing, small Russian clinical reports, WADA status and published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/pt-141/https://independentpeptidenews.com/peptides/pt-141/Mon, 02 Nov 2026 12:00:00 +0000PT-141 dossier: the FDA-approved Vyleesi label, the RECONNECT phase 3 trials and a published critique, WADA and HHS status, and 2026 FDA warning letters about unapproved PT-141 products, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/pinealon/https://independentpeptidenews.com/peptides/pinealon/Mon, 02 Nov 2026 12:00:00 +0000Pinealon dossier: the few published studies, which come from one Russian research program, and what FDA, WADA and registries do and do not say, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/oxytocin/https://independentpeptidenews.com/peptides/oxytocin/Mon, 02 Nov 2026 12:00:00 +0000Oxytocin dossier: the FDA-approved injection labels, the labor-induction limits, trial counts, and what we did and did not find about nasal oxytocin, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/hexarelin/https://independentpeptidenews.com/peptides/hexarelin/Mon, 02 Nov 2026 12:00:00 +0000Hexarelin dossier: WADA status, the small human studies and mostly animal research, and what FDA does and does not say, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/ghrp-2/https://independentpeptidenews.com/peptides/ghrp-2/Mon, 02 Nov 2026 12:00:00 +0000GHRP-2 dossier: FDA safety-risk listing, its use as a diagnostic test, WADA status and published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/epitalon/https://independentpeptidenews.com/peptides/epitalon/Mon, 02 Nov 2026 12:00:00 +0000Epitalon dossier: FDA briefing and safety-risk listing, HHS enforcement policy, WADA status, registry, published research and SEC filing, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/aod-9604/https://independentpeptidenews.com/peptides/aod-9604/Mon, 02 Nov 2026 12:00:00 +0000AOD-9604 dossier: FDA safety-risk listing, the sponsor’s obesity trial, WADA status and published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/tirzepatide/https://independentpeptidenews.com/peptides/tirzepatide/Sun, 01 Nov 2026 12:00:00 +0000Tirzepatide dossier: FDA approvals, label boxed warning, the shortage and compounding timeline, FDA statements on compounded product, trial records and key papers, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/thymosin-alpha-1/https://independentpeptidenews.com/peptides/thymosin-alpha-1/Sun, 01 Nov 2026 12:00:00 +0000Thymosin alpha-1 dossier: FDA safety-risk listing, 66 registered studies, randomized trials with mixed results, approvals abroad, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/tesamorelin/https://independentpeptidenews.com/peptides/tesamorelin/Sun, 01 Nov 2026 12:00:00 +0000Tesamorelin dossier: the FDA-approved Egrifta labels, the pivotal trial, WADA status and 2026 FDA warning letters about unapproved tesamorelin products, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/sermorelin/https://independentpeptidenews.com/peptides/sermorelin/Sun, 01 Nov 2026 12:00:00 +0000Sermorelin dossier: the discontinued GEREF approvals, FDA’s 2013 determination, WADA status and published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/semaglutide/https://independentpeptidenews.com/peptides/semaglutide/Sun, 01 Nov 2026 12:00:00 +0000Semaglutide dossier: FDA approvals, label boxed warning, the shortage and compounding timeline, FDA statements on compounded and counterfeit product, trial records and key papers, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/retatrutide/https://independentpeptidenews.com/peptides/retatrutide/Sun, 01 Nov 2026 12:00:00 +0000Retatrutide dossier: investigational status, FDA statement that it cannot be compounded, FDA warning letters, phase 3 trial records and published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/kisspeptin-10/https://independentpeptidenews.com/peptides/kisspeptin-10/Sun, 01 Nov 2026 12:00:00 +0000Kisspeptin-10 dossier: FDA safety-risk listing, academic trials, WADA status and published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/ipamorelin/https://independentpeptidenews.com/peptides/ipamorelin/Sun, 01 Nov 2026 12:00:00 +0000Ipamorelin dossier: FDA safety-risk listing, two phase 2 trials, 2026 warning letters, WADA status and published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/ibutamoren/https://independentpeptidenews.com/peptides/ibutamoren/Sun, 01 Nov 2026 12:00:00 +0000Ibutamoren (MK-677) dossier: FDA safety-risk listing and heart failure signal, completed trials, a pediatric phase 3, WADA status, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/ghrp-6/https://independentpeptidenews.com/peptides/ghrp-6/Sun, 01 Nov 2026 12:00:00 +0000GHRP-6 dossier: FDA safety-risk listing, its use as a diagnostic test, WADA status and published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/cjc-1295/https://independentpeptidenews.com/peptides/cjc-1295/Sun, 01 Nov 2026 12:00:00 +0000CJC-1295 dossier: FDA briefing and advisory committee, safety-risk listing, the terminated 2006 trial, WADA status, published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/cagrilintide/https://independentpeptidenews.com/peptides/cagrilintide/Sun, 01 Nov 2026 12:00:00 +0000Cagrilintide dossier: not approved alone, CagriSema NDA filed, FDA statement that it cannot be compounded, phase 3 trial records and published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/tb-500/https://independentpeptidenews.com/peptides/tb-500/Sat, 31 Oct 2026 12:00:00 +0000TB-500 dossier: FDA briefing and safety-risk listing, WADA status, registry record, published research and SEC filings, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/peg-mgf/https://independentpeptidenews.com/peptides/peg-mgf/Sat, 31 Oct 2026 12:00:00 +0000PEG-MGF dossier: FDA safety-risk listing, HHS enforcement status, WADA listing of mechano growth factors, published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/mots-c/https://independentpeptidenews.com/peptides/mots-c/Sat, 31 Oct 2026 12:00:00 +0000MOTS-c dossier: FDA briefing and safety-risk listing, HHS enforcement policy, WADA S4 listing, registry and published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/melanotan-ii/https://independentpeptidenews.com/peptides/melanotan-ii/Sat, 31 Oct 2026 12:00:00 +0000Melanotan II dossier: FDA safety-risk listing with case-report adverse events, small clinical trials, FDA enforcement, WADA status and a registered trial, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/ll-37/https://independentpeptidenews.com/peptides/ll-37/Sat, 31 Oct 2026 12:00:00 +0000LL-37 dossier: FDA safety-risk listing, HHS enforcement status, WADA status, registered trials and published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/kpv/https://independentpeptidenews.com/peptides/kpv/Sat, 31 Oct 2026 12:00:00 +0000KPV dossier: FDA briefing and safety-risk listing, HHS enforcement policy, WADA status, registry and published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/ghk-cu/https://independentpeptidenews.com/peptides/ghk-cu/Sat, 31 Oct 2026 12:00:00 +0000GHK-Cu (copper peptide) dossier: FDA safety-risk listing for injectable routes, HHS enforcement status, WADA status, registered trials and published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/emideltide/https://independentpeptidenews.com/peptides/emideltide/Sat, 31 Oct 2026 12:00:00 +0000Emideltide (DSIP) dossier: FDA briefing, advisory committee outcome, safety-risk listing, WADA status, published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/dihexa/https://independentpeptidenews.com/peptides/dihexa/Sat, 31 Oct 2026 12:00:00 +0000Dihexa dossier: FDA safety-risk listing, a retracted key paper, expressions of concern, SEC disclosures, WADA status and published research, each linked to the primary document. Volunteer-run. Not medical advice. https://independentpeptidenews.com/peptides/bpc-157/https://independentpeptidenews.com/peptides/bpc-157/Sat, 31 Oct 2026 12:00:00 +0000BPC-157 dossier: FDA actions and warning letters, WADA status, registered trials, patents and SEC filings, each linked to the primary document. Volunteer-run. Not medical advice.